

For further information, contact:

Dr. Robert B. Harris

President/CEO, CBI

Phone: 800 735 9224

Fax: 804 648 2641

**Commonwealth Biotechnologies, Inc. to Present at the New York
Society of Security Analysts**

Company seeks improved analyst coverage

Newsletter directed at clients and investors also announced

RICHMOND, VA (November 29, 2005) - Commonwealth Biotechnologies, Inc. (CBI) (NASDAQ Capital Market: CBTE), today announced that Dr. Robert B. Harris, President and CEO and Dr. Richard J. Freer, Chair and COO, have been invited to present a corporate overview Thursday, December 15 at 3:30 pm during the 2005 Specialty Pharma and Biotech conference, sponsored by the New York Society of Security Analysts (NYSSA), taking place at the Harvard Club in New York City. Dr. Harris' presentation will be available on the Company webpage at www.cbi-biotech.com a few days after December 15th.

"The company is extending its investor relations program to a more public forum in order to increase analyst and investor awareness of the CBI story", said Richard J. Freer, Chairman and COO of the company. "In the past, the company has not done a very good job of making the public aware of the unique nature of the company and its position in the biotech industry. We will aggressively do so in the future and we feel this presentation to the 9,000 member NYSSA will be an important first step towards correcting that situation", he added.

In addition, the company announced the planned launch of its electronic quarterly newsletter, *The CBI Messenger*, set for January 2006. This newsletter will seek to inform both clients and investors of the important activities ongoing at CBI .

About CBI

Commonwealth Biotechnologies, Inc. is a solutions provider to the global biotechnology industry, academic institutions, government agencies, and pharmaceutical companies. It offers broad ranging expertise and a complete array of the most current analytical and synthetic chemistries and biophysical analysis technologies, many of which are not available from other commercial sources. CBI has crafted a stimulating, open environment where scientists collaborate among themselves and with our clients, take on interesting challenges and develop creative solutions. Through its FIL division, CBI offers comprehensive genetic identity testing, including paternity, forensic, and CODIS analyses. CBI is accredited by the American Association of Blood Banks, CLIA, and the National Forensic Science Technology Council, and operates fully accredited BSL-3 laboratory. For more information, visit CBI on the web at www.cbi-biotech.com and visit FIL at www.fairfaxidlab.com.

#

Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in the Company's filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. No statement herein should be considered an offer of any securities.